PAVmed Inc. (PAVM) stock
PAVMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$1.51−0.24 (-13.71%)
Close on Nov 17, 2026Market cap $12.07MP/E –Yield –
PAVmed r&d expenses
Research and development expenses are spending on new products and technology.
PAVmed's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.37M, up 62.3% year over year. For fiscal 2025 it was $4.49M, down 24.3% from the year before. Over ten years it grew 24.8% a year on average. The highest annual figure on record is $25.34M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.49M | -24.3% |
| FY2024 | Dec 31, 2024 | $5.93M | -58.4% |
| FY2023 | Dec 31, 2023 | $14.28M | -43.7% |
| FY2022 | Dec 31, 2022 | $25.34M | +27.7% |
| FY2021 | Dec 31, 2021 | $19.85M | +81.0% |
| FY2020 | Dec 31, 2020 | $10.96M | +65.4% |
| FY2019 | Dec 31, 2019 | $6.63M | +55.9% |
| FY2018 | Dec 31, 2018 | $4.25M | +62.2% |
| FY2017 | Dec 31, 2017 | $2.62M | +52.5% |
| FY2016 | Dec 31, 2016 | $1.72M | +251.4% |
| FY2015 | Dec 31, 2015 | $489.33K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.07M | +161.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.39M | +76.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.83M | +126.5% |
| Q3 FY2025 | Sep 30, 2025 | $1.09M | -29.4% |
| Q2 FY2025 | Jun 30, 2025 | $790.00K | -51.9% |
| Q1 FY2025 | Mar 31, 2025 | $787.00K | -59.5% |
| Q4 FY2024 | Dec 31, 2024 | $807.00K | -77.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.54M | -51.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.64M | -52.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.94M | -52.1% |
| Q4 FY2023 | Dec 31, 2023 | $3.60M | -46.1% |
| Q3 FY2023 | Sep 30, 2023 | $3.16M | -49.0% |
| Q2 FY2023 | Jun 30, 2023 | $3.47M | -48.5% |
| Q1 FY2023 | Mar 31, 2023 | $4.05M | -31.7% |
| Q4 FY2022 | Dec 31, 2022 | $6.67M | -4.2% |
| Q3 FY2022 | Sep 30, 2022 | $6.20M | +16.9% |
| Q2 FY2022 | Jun 30, 2022 | $6.74M | +58.3% |
| Q1 FY2022 | Mar 31, 2022 | $5.93M | +78.9% |
| Q4 FY2021 | Dec 31, 2021 | $6.97M | +91.4% |
| Q3 FY2021 | Sep 30, 2021 | $5.31M | +102.6% |
| Q2 FY2021 | Jun 30, 2021 | $4.26M | +99.6% |
| Q1 FY2021 | Mar 31, 2021 | $3.32M | +26.1% |
| Q4 FY2020 | Dec 31, 2020 | $3.64M | +61.6% |
| Q3 FY2020 | Sep 30, 2020 | $2.62M | +72.3% |
| Q2 FY2020 | Jun 30, 2020 | $2.13M | +51.8% |
| Q1 FY2020 | Mar 31, 2020 | $2.63M | +81.1% |
| Q4 FY2019 | Dec 31, 2019 | $2.25M | +64.8% |
| Q3 FY2019 | Sep 30, 2019 | $1.52M | +29.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.41M | +22.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.45M | +157.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.37M | +145.1% |
| Q3 FY2018 | Sep 30, 2018 | $1.17M | +66.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.15M | +63.7% |
| Q1 FY2018 | Mar 31, 2018 | $563.22K | -14.2% |
| Q4 FY2017 | Dec 31, 2017 | $558.21K | -8.0% |
| Q3 FY2017 | Sep 30, 2017 | $704.87K | +21.8% |
| Q2 FY2017 | Jun 30, 2017 | $701.74K | – |
| Q1 FY2017 | Mar 31, 2017 | $656.71K | – |
| Q4 FY2016 | Dec 31, 2016 | $606.97K | – |
| Q3 FY2016 | Sep 30, 2016 | $578.47K | – |
See a number that looks wrong?